ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.

Giulio Francolini,Pietro Garlatti,Mauro Loi,Beatrice Detti,Michele Aquilano,Andrea Gaetano Allegra,Barbara Guerrieri,V. Salvestrini,Pamela Pinzani,Chiara Bellini,Francesca Salvianti,G. Stocchi,Lucia Pia Ciccone,Giulia Salvatore,Mariangela Sottili,Vanessa Di Cataldo,Isacco Desideri,Monica Mangoni,Icro Meattini,Lorenzo Livi

ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.

2021

118Background: Androgen Receptor Targeted Agents (ARTA) represent one of the main treatment options for metastatic castrate resistant prostate cancer (mCRPC). Addition of stereotactic radiation the...

Keywords:

Oncology
Abiraterone acetate
Androgen receptor
Prostate cancer
Castrate-resistant prostate cancer
castration resistant
Circulating tumor cell
stereotactic body radiation therapy
Medicine
Internal medicine
first line

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations